Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Aphria Inc. APHA

Aphria, which is headquartered in Ontario, produces and sells medicinal and recreational cannabis. The company operates through retail and wholesale channels in Canada and internationally. Aphria is a main distributor of medical cannabis to Germany and has operations in over 10 countries outside of Canada. However, it does not have exposure to the U.S. CBD or THC markets due to the constraints of federal prohibition. It has some U.S. exposure through the acquisition of SweetWater, a craft brewer


NDAQ:APHA - Post by User

Bullboard Posts
Post by Bitofgreenon Aug 09, 2019 5:12pm
119 Views
Post# 30013038

Long Perspective

Long PerspectiveI don’t think we need to work ourselves into a lather. Gains will materialize when revenues and profits take center stage. No speculative news will supersede fundamentals at this point. Given the turnaround initiated by Irwin and the new team, perhaps we should trust his leadership. He has earned it IMO.  I have been long and through the wars and try to avoid most of the noise. If you believe in the company actually as an investment and not a trade the current action is opportunity.  Irwin did say CANNTRUST has good assets and last time I looked, administrative malpractice did not affect the physical assets or more importantly, the clinical research.  These types of assets could be considerable and worth more than all the brick and mortar combined. I say we trust our new team to evaluate and make the right decisions. If you don’t like what’s going on then you all have options.  
Bullboard Posts